NCT00135317View on ClinicalTrials.gov

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2004

Conditions
Cancer
Interventions
DRUG

darbepoetin alfa

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY